Vertex Pharmaceuticals Incorporated (VRTX) has been benefiting from strong revenue growth, regulatory approvals and commercial launches in the past year. Vertex enjoys a dominant position in the cystic fibrosis (CF) market. Vertex’s CF sales continue to grow, driven by its triple therapy, Trikafta (marketed as Kaftrio in Europe). In the United States, Trikafta sales are being fueled by label expansions to younger age groups (two to five years old). In the ex-U.S. markets, the drug continues to witness stron ...